Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents
Language English Country Netherlands Media print-electronic
Document type Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
28215530
DOI
10.1016/bs.ircmb.2016.09.003
PII: S1937-6448(16)30098-3
Knihovny.cz E-resources
- Keywords
- Chemotherapy, Damage-associated molecular patterns, Dendritic cell, Immunogenic cell death, Immunotherapy,
- MeSH
- Dendritic Cells immunology MeSH
- Immunotherapy MeSH
- Clinical Trials as Topic MeSH
- Humans MeSH
- Antineoplastic Agents therapeutic use MeSH
- Cancer Vaccines immunology MeSH
- Vaccination * MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Antineoplastic Agents MeSH
- Cancer Vaccines MeSH
Owing to their central role in the initiation and regulation of antitumor immunity, dendritic cells (DCs) have been widely tested for use in cancer immunotherapy. Despite several encouraging clinical applications, existing DC-based immunotherapy efforts have yielded inconsistent results. Recent work has identified strategies that may allow for more potent DC-based vaccines, such as the combination with antitumor agents that have the potential to synergistically enhance DC functions. Selected cytotoxic agents may stimulate DCs either by directly promoting their maturation or through the induction of immunogenic tumor cell death. Moreover, they may support DC-induced adaptive immune responses by disrupting tumor-induced immunosuppressive mechanisms via selective depletion or inhibition of regulatory subsets, such as myeloid-derived suppressor cells and/or regulatory T cells (Tregs). Here, we summarize our current knowledge on the capacity of anticancer chemotherapeutics to modulate DC phenotype and functions and the results of ongoing clinical trials evaluating the use of DC-based immunotherapy in combination with chemotherapy in cancer patients.
2nd Faculty of Medicine and University Hospital Motol Prague Czech Republic
Faculty of Medicine and Faculty Hospital in Hradec Kralove Charles University Prague Czech Republic
References provided by Crossref.org
Detection of immunogenic cell death and its relevance for cancer therapy
Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
